Characterization of Pseudomonas aeruginosa Bacteriophage L5 Which Requires Type IV Pili for Infection
- PMID: 35847060
- PMCID: PMC9284122
- DOI: 10.3389/fmicb.2022.907958
Characterization of Pseudomonas aeruginosa Bacteriophage L5 Which Requires Type IV Pili for Infection
Abstract
Pseudomonas aeruginosa is a common opportunistic human pathogen. With the emergence of multidrug-resistant (MDR) clinical infection of P. aeruginosa, phage therapy has received renewed attention in treating P. aeruginosa infections. Moreover, a detailed understanding of the host receptor of lytic phage is crucial for selecting proper phages for therapy. Here, we describe the characterization of the P. aeruginosa bacteriophage L5 with a double-stranded DNA genome of 42,925 bp. The genomic characteristics indicate that L5 is a lytic bacteriophage belonging to the subfamily Autographivirinae. In addition, the phage receptors for L5 were also identified as type IV pili, because the mutation of pilZ, which is involved in pili synthesis, resists phage infection, while the complementation of pilZ restored its phage sensitivity. This research reveals that L5 is a potential phage therapy candidate for the treatment of P. aeruginosa infection.
Keywords: Autographivirinae; Pseudomonas aeruginosa; phage (bacteriophage); phage receptors; phage-host interaction.
Copyright © 2022 Yang, Zhang, Li, Zheng, Tan, Wu, Wang and Zhu.
Conflict of interest statement
NW was employed by the company CreatiPhage Biotechnology Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures





Similar articles
-
Characterization of a new Pseudomonas aeruginosa Queuovirinae bacteriophage.Microbiol Spectr. 2024 Mar 5;12(3):e0371923. doi: 10.1128/spectrum.03719-23. Epub 2024 Feb 12. Microbiol Spectr. 2024. PMID: 38345389 Free PMC article.
-
The adsorption of Pseudomonas aeruginosa bacteriophage phiKMV is dependent on expression regulation of type IV pili genes.FEMS Microbiol Lett. 2009 Jun;296(2):210-8. doi: 10.1111/j.1574-6968.2009.01640.x. Epub 2009 May 4. FEMS Microbiol Lett. 2009. PMID: 19459952
-
Characterization of Pseudomonas lytic phages and their application as a cocktail with antibiotics in controlling Pseudomonas aeruginosa.J Biosci Bioeng. 2020 Jun;129(6):693-699. doi: 10.1016/j.jbiosc.2020.02.001. Epub 2020 Feb 24. J Biosci Bioeng. 2020. PMID: 32107153
-
Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections.Antibiotics (Basel). 2021 May 11;10(5):556. doi: 10.3390/antibiotics10050556. Antibiotics (Basel). 2021. PMID: 34064648 Free PMC article. Review.
-
The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways.J Cyst Fibros. 2017 Nov;16(6):663-670. doi: 10.1016/j.jcf.2017.06.012. Epub 2017 Jul 15. J Cyst Fibros. 2017. PMID: 28720345 Review.
Cited by
-
Phages ZC01 and ZC03 require type-IV pilus for Pseudomonas aeruginosa infection and have a potential for therapeutic applications.Microbiol Spectr. 2024 Oct 29;12(12):e0152724. doi: 10.1128/spectrum.01527-24. Online ahead of print. Microbiol Spectr. 2024. PMID: 39470273 Free PMC article.
-
Biocontrol of Phage Resistance in Pseudomonas Infections: Insights into Directed Breaking of Spontaneous Evolutionary Selection in Phage Therapy.Viruses. 2025 Aug 4;17(8):1080. doi: 10.3390/v17081080. Viruses. 2025. PMID: 40872794 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources